Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics’ results for the second fiscal quarter of 2026 missed expectations on earnings, with EPS of -$0.18 trailing the -$0.10 estimate by -$0.07, in results reported August 11, 2026. Revenue rose 38% year over year to about $13.8 million, up from roughly $10.0 million a year ago, alongside gross profit of about $9.8 million as gross margin ran near 71%. Operating results remained negative, with operating income of roughly -$8.2 million and operating margin around -60%, while the bottom line posted net income of about -$22.9 million versus roughly -$13.5 million a year ago. On a per-share basis, EPS was down 29% from -$0.14 a year earlier. Cash generation was also negative, with operating cash flow of roughly -$9.4 million in the quarter. Next-period consensus calls for EPS of -$0.11 on revenue of $11.0 million.